Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.

Cancer research - 2 Sept 2025

DiMarco Ashley V, Ravichandran Mirunalini, Lau Jeff, Lima Anthony, Lacap Jennifer, Saenz-Lopez Larrocha Pablo, Lin Eva, Weng Julie, Gerosa Luca, Hunsaker Thomas, Xiao Yang, Miś Monika, Havnar Charles, Chen Wennie, Barck Kai H, Totpal Klara, Foreman Oded, Sodir Nicole M, Merchant Mark, Maddalo Danilo

Abstract excerpt

RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are considered "oncogene-negative" and are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinogenesis

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to ras Proteins

Source

Identifiers

PMID: 40608319
DOI: 10.1158/0008-5472.CAN-24-3662

Genes

RIT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.PMID 40608319Read ↗

RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapySemantic proximity Read ↗

RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.Semantic proximity Read ↗

Oncogenic RIT1 mutations in lung adenocarcinoma.Semantic proximity Read ↗

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma.Semantic proximity Read ↗

Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer stateSemantic proximity Read ↗

An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancerSemantic proximity Read ↗

Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.Semantic proximity Read ↗

The molecular functions of RIT1 and its contribution to human disease.Semantic proximity Read ↗

Mapping the unique and shared functions of oncogenic KRAS and RIT1 with proteome and transcriptome profilingSemantic proximity Read ↗

Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study.Semantic proximity Read ↗

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.